Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib

INTRODUCTION: The effectiveness of nivolumab plus cabozantinib for metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus remains unclear. CASE PRESENTATION: A 77‐year‐old male was diagnosed with right papillary renal cell carcinoma with a metastatic lesion on Gerota's...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashida, Michikata, Miura, Yuji, Yamaguchi, Takeshi, Tanaka, Makoto, Yamanaka, Taro, Takemura, Kohji, Oka, Suguru, Sakaguchi, Kazushige, Ito, Shinji, Urakami, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622194/
https://www.ncbi.nlm.nih.gov/pubmed/37928303
http://dx.doi.org/10.1002/iju5.12638
Descripción
Sumario:INTRODUCTION: The effectiveness of nivolumab plus cabozantinib for metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus remains unclear. CASE PRESENTATION: A 77‐year‐old male was diagnosed with right papillary renal cell carcinoma with a metastatic lesion on Gerota's fascia, lymph node metastasis, and inferior vena cava tumor thrombus. He was treated with nivolumab plus cabozantinib. As all lesions regressed enough to permit complete resection, radical nephrectomy, thrombectomy, and retroperitoneal lymph node dissection were performed. No viable malignant cells were identified histopathologically. Despite the discontinuation of nivolumab plus cabozantinib, there has been no recurrence for 9 months. CONCLUSION: Nivolumab plus cabozantinib has effectiveness for metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus.

Ejemplares similares